Subscribe 600$/product give away!
Submit an Article to Pharmacy HQ     
Please include the author's name, title, and citations.     

AFLURIA (influenza a virus a/california/7/2009 x-181 (h1n1) antigen (propiolactone inactivated), influenza a virus a/texas/50/2012 x-223 (h3n2) antigen (propiolactone inactivated), and influenza b virus b/massachusetts/2/2012 bx-51b antigen- propiolactone inactivated injection, suspension

Patient Information

  • Inform the vaccine recipient or guardian of the potential benefits and risks of immunization with AFLURIA.
  • Inform the vaccine recipient or guardian that AFLURIA is an inactivated vaccine that cannot cause influenza but stimulates the immune system to produce antibodies that protect against influenza, and that the full effect of the vaccine is generally achieved approximately 3 weeks after vaccination.
  • Instruct the vaccine recipient or guardian to report any severe or unusual adverse reactions to their healthcare provider.
  • Provide the vaccine recipient or guardian with Vaccine Information Statements which are required by the National Childhood Vaccine Injury Act of 1986 to be given prior to immunization. These materials are available free of charge at the Centers for Disease Control and Prevention (CDC) website (
  • Instruct the vaccine recipient or guardian that annual revaccination is recommended.

Manufactured by:
bioCSL Pty Ltd.
Parkville, Victoria, 3052, Australia
US License No. 2002

Distributed by:
bioCSL Inc.1020 First Avenue, King of Prussia, PA 19406, USA

AFLURIA is a registered trademark of CSL Limited used under license. bioCSL Pty Ltd. and bioCSL Inc. are subsidiaries of CSL Limited.
PharmaJetand STRATISare registered trademarks of PharmaJet.

Your use of this website constitutes your agreement to the terms and conditions linked below:
Terms and Conditions | Resources | Sitemap
2017 © Copyright Questions?
Please contact: